Sanofi’s Insulin Aspart Biosimilar Receives EMA Authorization

Last week, the EMA authorized Insulin aspart Sanofi’s biosimilar product. The EMA notes on its website that Insulin aspart Sanofi is “highly similar to another biological medicine [NovoRapid] that is already authorized in the EU.” Insulin aspart Sanofi contains the active substance insulin aspart, a rapid-acting insulin, and received marketing authorization valid throughout the EU on June 25, 2020.

The post Sanofi’s Insulin Aspart Biosimilar Receives EMA Authorization appeared first on Big Molecule Watch.